shown that patients with nonmuscle invasive bladder cancer (NMIBC) and specifically CIS who fail BCG and progress to muscle Invasive bladder cancer (secondary MIBC) do worse after radical cystectomy (RC) than patients who present with de-novo MIBC. We have previously demonstrated favorable results in a highly selected cohort of patients with clinical complete response (cCR) after neoadjuvant platinumbased chemotherapy (NAC) who forego radical cystectomy (RC) and are placed on an active surveillance and delayed intervention (ASDI) protocol. We sought to investigate whether secondary MIBC or CIS on pre-NAC TUR had worse outcomes than de-novo MIBC in our ASDI cohort.
INTRODUCTION AND OBJECTIVES: Prior studies have
shown that patients with nonmuscle invasive bladder cancer (NMIBC) and specifically CIS who fail BCG and progress to muscle Invasive bladder cancer (secondary MIBC) do worse after radical cystectomy (RC) than patients who present with de-novo MIBC. We have previously demonstrated favorable results in a highly selected cohort of patients with clinical complete response (cCR) after neoadjuvant platinumbased chemotherapy (NAC) who forego radical cystectomy (RC) and are placed on an active surveillance and delayed intervention (ASDI) protocol. We sought to investigate whether secondary MIBC or CIS on pre-NAC TUR had worse outcomes than de-novo MIBC in our ASDI cohort.
METHODS: A single institution IRB-approved urologic oncology database was retrospectively reviewed to identify secondary MIBC and CIS in a cohort of 52 cCR response ASDI patients. A cCR to NAC was defined as negative TURBT, urine cytology, and cross-sectional imaging. Patients on the ASDI protocol were followed with cystoscopy, urine cytology, and cross-sectional imaging at 3-4 month intervals. Kaplan Meier curves and cox regression models were used to identify predictors of recurrence.
RESULTS: Secondary MIBC was identified in 14/52 (26.9%) within the ASDI cohorteall but 1 had documented prior BCG treatment. CIS was present within 21/52 (40%) of pre-NAC TUR specimens. Recurrence risk was similar when stratifying by secondary MIBC vs de-novo MIBC but trended towards increased recurrence risk when stratified by CIS (HR 1.76, p [ 0.111,  figure 1) . 5-year cancerspecific, overall, and cystectomy-free survival were similar between groups at 85%, 81% and 60%, respectively. 13/31 (42%) of recurrences were managed conservatively while the remainder underwent RC. On multivariable cox regression controlling for age and hydronephrosis, secondary MIBC was not a significant predictor (HR 0.426, p [ 0.15) , but CIS (HR 2.7, p [ 0.012) and hydronephrosis (HR 2.9, p [ 0.022) both increased risk of relapse.
CONCLUSIONS: While recent studies have suggested that secondary MIBC may be less chemosensitive than de-novo MIBC, when secondary MIBC completely responds to NAC, outcomes on the ASDI protocol are similar. A diagnosis of CIS on pre-NAC TURBT warrants heightened vigilance for recurrence should the patient pursue bladder preservation. METHODS: In this retrospective study from a tertiary university hospital, we identified 469 patients who underwent RC from 2010 to 2016. Patient cohorts were stratified by presence of LVI on TURBT prior to RC. Clinical variables evaluated included age, BMI, CCI, receipt of neoadjuvant chemotherapy (NAC), 30 day complication rates, pathological upstaging, LNP at time of RC, lymph node yield, and final pathological stage. Chi-square test of independence was used to test for associations between LVI and clinical variables. Overall survival (OS) and disease-free survival (DFS) were calculated with KaplanMeier method.
RESULTS: 62 patients were found to have LVI present on TURBT and 407 patients had either no LVI or no mention of LVI on pathology report. Results are summarized in figure 1. Pathological upstaging occurred in 64.5% of the LVI group and 45.7% of the no LVI group (p[0.006) and LNP at RC was identified in 46.8% of the LVI group and 23.4% of the no LVI group (p<0.001). Final pathologic stage was overall higher in the LVI group with 77.5% having !pT2 compared to 59.5% in the no LVI group (p<0.001). Multivariate analysis demonstrated that LVI was independently associated with probability of upstaging (OR: 2.31, 95% CI: 1.30 e 4.09, p[0.004) and LNP (OR: 1.97, 95% CI: 1.04 e 3.71, p[0.037). Further, there was a significant decrease found in OS and DFS for patients with LVI present on TURBT, (p<0.001).
CONCLUSIONS: Patients with LVI at time of TURBT had higher risk for LN positive disease and pathologic upstaging at time of RC. Further, LVI was associated with worse OS and DFS. These results suggest that patients with LVI at time of TURBT may benefit from more aggressive therapy, such as early RC, or receipt of NAC independent of stage.
INTRODUCTION AND OBJECTIVES:
A good pelvic lymph node dissection (PLND) during radical cystectomy (RC) is a standard of practice. Although the extent of PLND is debatable, the progressionfree survival and overall survival have been correlated with the number of nodes removed during surgery. The sentinel marker of lymph node dissection which is the lymph node density (LNd) is not used in routine practice as a prognostic variable.
OBJECTIVE: To evaluate the prognostic value of LNd in Ca Bladder and to evaluate a cut off value of LNd that correlates with prognosis and survival for patients undergoing RCþPLND.
METHODS: The records of patients undergoing upfront RC þ PLND over consecutive five years in a cancer institute, were analysed retrospectively excluding those who received neoadjuvant chemotherapy or treatment failures following bladder conservation therapy.
RESULTS: A total of 152 patients were analysed (M:F 139:13) with median age of 62 years. 76 (50.7%) were found to have nodal metastasis out of which 34 were found to have perinodal extension. 59 (77.6%) received adjuvant chemotherapy and 16 (21.1%) received postoperative radiotherapy. One patient was given postoperative chemo-radiation. At median follow up of 60 months, 47 of the 150 patients had died of the disease. The median lymph nodes yield was 17 (6-36). On univariate analysis number of lymph nodes dissected did not correlate with survival. However pT stage, presence of perinodal extension and LNd were all found to affect survival significantly in both univariate and multivariate analysis with a hazard ratio of 3.23 for perinodal extension. LNd of less than 10% did not correlate with survival but a range between 10-20% and > 20% showed a hazard ratio of 3.9 and 6.6 respectively. The mean survival for patients with node negative disease was 109 months which reduced to 24 months amongst patients with LNd of > 0.21. LNd cutoff value of 15% was found to be most relevant and applicable for survival.
CONCLUSIONS: Lymph node density is the one of strongest predictor of overall survival in urinary bladder cancer. A proposed lymph node density threshold of 15% correlates well with recurrence and survival and for prognostication.
Source of Funding: Nil

PD57-04 MOLECULAR PREDICTORS OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY AND PROGNOSIS IN MUSCLE-INVASIVE BLADDER CANCER
Mauro Ragonese*, Luca Di Gianfrancesco, Giovanni Schinzari, Giuseppe Palermo, Marco Racioppi, PierFrancesco Bassi, Rome, Italy INTRODUCTION AND OBJECTIVES: Multiple molecular biomarkers have been proposed as predictors of neoadjuvant chemotherapy efficacy in urothelial muscle-invasive bladder cancer. Despite emerging evidences, these data are not yet translated into clinical practice. Our study evaluates the prognostic and predictive role of the expression of the human equilibrative nucleoside transporter 1 (hENT1) and the excision repair cross complementing 1 (ERCC1) in bladder cancer receiving neoadjuvant chemotherapy with gemcitabine and platinum derivatives.
METHODS: Clinical records of forty patients with muscleinvasive bladder cancer who received neoadjuvant gemcitabineplatinum combination chemotherapy were retrospectively analyzed. The primary endpoint was histopathologic complete response (pCR) rate and the secondary endpoints were disease-free survival (DFS) and overall survival (OS). Clinical and histopathologic parameters along with ERCC1 and hENT1 expression, assessed by RT-PCR in chemo-naive primary bladder tumor specimen, were examined and correlated with pCR rates, DFS and OS. To test the hypothesis that patients with hENT1þve and low ERCC1 level tumors had better outcomes, an exploratory analysis of pCR rate was performed in two prognostic subgroups: subgroup A, containing hENT1þve and low ERCC1 level population; subgroup B, containing hENT1-ve and high ERCC1 level population plus patients having both expressions of hENT1 and ERCC1 with same tendency.
RESULTS: pCR rate in the whole population was 40% (16 out of 40 patients), while in hENT1þve and low ERCC1 level population (subgroup A) was 61.5% (16 out of 26 patients) which was signicantly higher than in patients with either both expressions of biomarerks with
